Le professeur Louis Dubertret, ex-président de la fondation René Touraine, nous explique les fausses opinions qu’accompagnent souvent un individu atteint par la maladie.
Le psoriasis est-il contagieux ?
Non. Vous pouvez, par exemple, aller à la piscine avec du psoriasis sans aucun risque. Au contraire, la peau psoriasique, avec ses plaques, contient bien plus de molécules anti-infectieuses qu’une peau normale. Il s’agit donc d’une peau qui s’infecte beaucoup moins qu’une autre.
Le psoriasis est-il héréditaire ?
Ce question est récurrente car le psoriasis a une origine génétique. Cependant, cette transmission se réalise non pas de manière mathématique ou monogénique, mais bien comme un "terrain" favorable aux membres d’une même famille. De la même manière qu’une mère atteinte régulièrement de rhumes des foins a des enfants qui présentent le risque de le développer, un parent atteint de psoriasis aura des enfants risquant de developper cette pathologie plus que la moyenne. Cette inquiétude se retrouve souvent chez un futur parent souffrant de psoriasis sévère. Mais il faut savoir que dans ce cas-là, le mélange de ses gènes avec ceux de l’autre parent ne peut, au pire, qu’entraîner un psoriasis plus modéré chez l’enfant. Aussi, le développement de traitements de plus en plus efficaces doit nous faire sortir de la vision du psoriasis comme une malédiction transmise de génération en génération.
Si mon traitement ne me convient pas, dois-je changer de médecin ?
En raison de ses symptômes variables pour chaque individu, le psoriasis fait partie de ces maladies où le patient dispose d’informations précieuses sur sa condition que le médecin ne peut connaître. De ce fait, le patient doit les lui communiquer régulièrement afin de bénéficier d’un ajustement continu de son traitement permettant de l’améliorer dans le temps. Changer perpétuellement de médecin est donc une erreur puisque cela compromet l’efficacité des soins. Il vaut donc mieux avoir la patience d’expliquer à son médecin de départ les causes de son insatisfaction afin que ce dernier, essai après essai, trouve le traitement idéal. Cela est d’autant plus important qu’aucun médecin ne peut tout savoir, surtout dans le cas d’une maladie s’exprimant différemment chez chaque personne.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
Bioorg. Med. Chem. Lett..
2020 Aug 15, 30, (16):127298.
We report on the discovery of the new clinical candidate BAY 1003803 as glucocorticoid receptor agonist for the topical treatment of psoriasis or severe atopic dermatitis. In the course of optimizing the amino alcohol series as a highly potent new non-steroidal lead structure, considerations were made as to how physicochemical properties and safety concerns relate to structural motifs. BAY 1003803 demonstrates strong anti-inflammatory activity in vitro paired with a pharmacokinetic profile (...)
see on pubmed
Immobilization of papain enzyme on a hybrid support containing zinc oxide nanoparticles and chitosan for clinical applications.
Carbohydr Polym.
2020 Sep 01, 243:116498.
A new hybrid bionanomaterial composed of zinc oxide nanoparticles (ZnO NPs) and chitosan was constructed after enzymatic immobilization of papain for biomedical applications. In this work, we report the preparation and characterization steps of this bionanomaterial and its biocompatibility in vitro. The properties of the immobilized papain system were investigated by transmission electron microscopy, zeta potential, DLS, UV-vis absorption spectroscopy, FTIR spectroscopy, and X-ray (...)
see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv.
2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)
see on pubmed
on Atopic Dermatitis
Diagnostic Models for Atopic Dermatitis Based on Serum Microbial Extracellular Vesicle Metagenomic Analysis: A Pilot Study.
Allergy Asthma Immunol Res.
2020 Sep , 12, (5):792-805.
Associations between a wide variety of diseases and the microbiome have been extensively verified. Recently, there has been a rising interest in the role the microbiome plays in atopic dermatitis (AD). Furthermore, metagenomic analysis of microbe-derived extracellular vesicles (EVs) has revealed the importance and relevance of microbial EVs in human health.
see on pubmed
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Jang H et al.
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Allergy Asthma Immunol Res.
2020 Sep , 12, (5):877-884.
The mitochondrial genome encodes core catalytic peptides that affect major metabolic processes within a cell. Here, we investigated the association between mitochondrial DNA (mtDNA) variants and allergic diseases, including atopic dermatitis (AD) and asthma, alongside heteroplasmy within the mtDNA in subjects with allergic sensitization. We collected genotype data from 973 subjects with allergic sensitization, consisting of 632 children with AD, 498 children with asthma, and 481 healthy (...)
see on pubmed
Update on canine filaggrin: a review.
Combarros D et al.
Update on canine filaggrin: a review.
Vet Q.
2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)
see on pubmed
